Study on the novel molecular classification and individual therapy for pancreatic neuroendocrine carcinoma.

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461041
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Aichi Cancer Center Research Institute
• Principal Investigator: Mizuno Nobumasa 愛知県がんセンター(研究所), 腫瘍免疫学部, 研究員 (80399592)
• Co-Investigator(Kenkyū-buntansha): 細田 和貴 愛知県がんセンター(研究所), 分子病態学部, 研究員 (00728412) ; 肱岡 範 国立研究開発法人国立がん研究センター, 中央病院肝胆膵内科, 医長 (50765394)
• Co-Investigator(Renkei-kenkyūsha): YATABE Yasushi 愛知県がんセンター(研究所), 分子腫瘍学部, 研究員 (90280809)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 膵神経内分泌癌 / KRAS / Rb / プラチナベース化学療法 / NET-G3 / NEC

Outline of Final Research Achievements

We examined the clinicopathological and molecular features of pancreatic neuroendocrine carcinoma (pNEC) based on the WHO2010 (WHO-NEC). 100 patients with pNEC were collected from 31 institutions. After central review characteristics of histological subtype (NET-G3 vs. poorly differentiated NEC (PDNEC)), 70 patients analyzed included 21 NETs-G3 (30%) and 49 PDNEC (70%). NET-G3 showed lower Ki67-LI (median 28.5%), no abnormal Rb expression (0%), and no mutated KRAS (0%), whereas PDNEC showed higher Ki67-LI (median 80.0%), Rb loss (54.5%), and KRAS mutations (48.7%). PanNENs-G3 with Rb loss and those with mutated KRAS showed significantly higher response rates to platinum-based chemotherapy (PBC) than those without (Rb loss, 80% vs. normal Rb, 24%, p=0.006; mutated KRAS, 77% vs. wild-type, 23%, p=0.023). NET-G3 and PDNEC showed distinct clinicopathological characteristics. Rb and KRAS are promising predictors of response to PBC for pNEC.

Free Research Field

消化器内科学、臨床腫瘍学